Altimmune (ALT) Stock Statistics & Valuation Metrics

Altimmune has a market cap or net worth of $548.42M. The enterprise value is $171.25M.

Altimmune has 194,474,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Altimmune’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -35.36%.

The current PE Ratio of Altimmune is ―. Altimmune’s PEG ratio is 0.14.

In the last 12 months, Altimmune had revenue of 41.00K and earned -88.09M in profits. Earnings per share was -1.00.

In the last 12 months, operating cash flow was -71.64M and capital expenditures -32.00K, giving a free cash flow of -71.67M billion.

Altimmune pays an annual dividend of $873, resulting in a dividend yield of ―

Altimmune upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Altimmune as a current ratio of 18.55, with Debt / Equity ratio of 12.62%

In the past 12 months, Altimmune has paid -681.00K in taxes.

Altimmune EV to EBITDA ratio is -3.56, with an EV/FCF ratio of -4.59.

Altimmune has $331.54M in cash and marketable securities with $35.85M in debt, giving a net cash position of $295.69M billion.

Gross margin is -41519.44%, with operating margin of -230460.98%, and net profit margin of -214860.98%.

The average price target for Altimmune is $12.70, which is 11.43% higher than the current price. The consensus rating is Moderate Buy